Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24

Articles

19391 items
1:06 PM, Jul 27, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 16 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 1Q; (B) Fiscal 3Q; (C) During trading hours in Europe; premarket on U.S. exchanges; (D) Six-month EPS CompanyDatePre/post...
12:59 PM, Jul 27, 2018  |  BioCentury | Finance

First out the gate

As Ascletis Pharma Inc. (HKSE:1672) prepares for its trading debut on Aug. 1, Hong Kong Exchanges and Clearing Ltd. (HKEX) market watchers hope investor demand for biotech in the region can maintain momentum. Ascletis priced...
12:59 PM, Jul 27, 2018  |  BioCentury | Finance

Manipulating microglia

Alector Inc.’s $133 million series E round provides enough runway for the immuno-neurology and immuno-oncology company to take at least five programs into the clinic in the next two years. Participants in the untranched round,...
12:11 PM, Jul 27, 2018  |  BioCentury | Emerging Company Profile

Wound-up bacteria

Ilya Pharma AB has engineered bacteria to produce a protein that promotes wound closure as a more convenient and lower cost alternative to recombinant protein therapies that accelerate wound healing. According to CEO Evelina Vågesjö,...
1:56 PM, Jul 26, 2018  |  BioCentury | Finance

Gossamer’s war chest

Gossamer Bio Inc. has built a huge war chest from investors lured by the prospect of near-term milestones, a plan for rapid pipeline growth and a winning management team from Receptos Inc. With Monday’s $230...
3:03 PM, Jul 23, 2018  |  BioCentury | Politics, Policy & Law

Azar’s political play with drug importation

The drug importation policy announced by Alex Azar last week is a political stunt, aimed at generating headlines at a time when the HHS secretary seems desperate to demonstrate to Donald Trump and the media...
7:33 PM, Jul 20, 2018  |  BioCentury | Politics, Policy & Law

Getting serious

HHS Secretary Alex Azar isn’t waiting for the ink to dry on the department’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, or for his staff to digest tens of thousands of pages of...
5:08 PM, Jul 20, 2018  |  BioCentury | Product Development

Getting to the point in IBS

A large epidemiological study set Ironwood Pharmaceuticals Inc. on a path to finding symptomatic outcomes important to IBS-C patients. The company’s new Phase IIIb study of Linzess linaclotide will probe those outcomes, seeking results that...
4:37 PM, Jul 20, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 18 profitable biotechs and pharmas are slated to report earnings this week. (A) Six-month EPS figures; (B) Fiscal 1Q CompanyDatePre/post mkt2Q18 EPS est2Q17 EPSExpected chgBiogen Inc. (NASDAQ:BIIB)7/24Pre$5.24$5.044%Eli Lilly and Co. (NYSE:LLY)7/24Pre$1.30$1.1117%Gilead Sciences...
4:07 PM, Jul 20, 2018  |  BioCentury | Regulation

FDA’s positive reinforcement

Companies are still sifting through a half dozen gene therapy guidance documents issued by FDA, but so far it appears the recommendations support the paths taken by some of the most advanced clinical candidates for...

Pages